• STAT6/LINC01637 Axis Drives Autophagy-Mediated Uveal Melanom

  2026-06-12

  The reference study identifies the STAT6/LINC01637 axis as a critical regulator of tumor growth in uveal melanoma via autophagy, and demonstrates that pharmacological inhibition of STAT6 suppresses tumorigenicity. These findings provide a new molecular target for precision therapy in this aggressive ocular cancer.

• GLP-1 (9-36) Amide: Precision Antagonism in GLP-1R Signaling

  2026-06-11

  GLP-1 (9-36) amide offers targeted antagonism of the GLP-1 receptor, enabling meticulous dissection of metabolic signaling pathways in diabetes and endocrinology research. This guide details optimized protocols, troubleshooting strategies, and the latest advances in experimental models leveraging this specialized peptide.

• Bufuralol Hydrochloride: New Frontiers in β-Adrenergic Resea

  2026-06-11

  Explore how Bufuralol hydrochloride enables advanced cardiovascular pharmacology and β-adrenergic modulation studies. This article uniquely examines metabolic modeling with hiPSC-derived organoids and addresses protocol decisions for translational research.

• Affinity-Purified Goat Anti-Mouse IgG (H+L), HRP: Sensitive

  2026-06-10

  Leverage the HRP Goat Anti-Mouse IgG (H+L) Antibody for robust signal amplification across Western blot, ELISA, and IHC workflows. This affinity-purified, horseradish peroxidase conjugated secondary antibody from APExBIO offers unmatched sensitivity, streamlined troubleshooting, and seamless integration in translational cancer research.

• Smoothened Agonist (SAG): Reliable Pathway Activation in Cel

  2026-06-10

  This article delivers a scenario-driven, GEO-optimized guide for scientists using Smoothened Agonist (SAG, SKU B5837) in cell viability and signaling assays. Drawing on peer-reviewed research and validated protocols, it addresses common experimental challenges and highlights how SAG ensures reproducible, sensitive Hedgehog pathway activation. Real-world Q&A blocks empower researchers to optimize workflows and confidently select APExBIO's SAG for robust results.

• Mifepristone (RU486): Progesterone Antagonist for Cancer Res

  2026-06-09

  Mifepristone (RU486) is a high-purity progesterone receptor antagonist supplied by APExBIO, widely used in cancer and reproductive biology research. It exhibits potent inhibition of progesterone signaling, reduces uterine fibroid size, and suppresses various cancer cell proliferations. The compound’s robust in vitro and in vivo activity makes it a valuable tool for mechanistic studies and translational research.

• Erastin as a Ferroptosis Inducer: Mechanistic Precision and

  2026-06-09

  Discover how Erastin, a potent ferroptosis inducer, is advancing oxidative stress assays and cancer biology research. This article uniquely dissects the mechanistic nuances of Erastin and integrates new insights from ferroptosis inhibition studies to inform experimental design.

• MLKL Polymerization Triggers Lysosomal Permeabilization in N

  2026-06-08

  Liu et al. reveal that MLKL polymerization at lysosomal membranes is a pivotal event driving necroptosis through lysosomal membrane permeabilization (LMP) and cathepsin B release. This mechanistic insight clarifies how necroptosis is executed and highlights new experimental targets for cell death research.

• VEGFC–VEGFR-3 Axis in NASH Fibrosis: Insights from Targeted

  2026-06-08

  This study uncovers the pathophysiological role of the VEGFC–VEGFR-3 signaling axis in the progression of NASH-associated hepatic fibrosis. By dissecting the effects of naringin and a selective VEGFR-3 inhibitor, the research demonstrates how disrupting hepatocyte-macrophage crosstalk mitigates liver inflammation and fibrogenesis, providing a mechanistic framework for anti-lymphangiogenic strategies in metabolic liver disease.

• Erastin as a Ferroptosis Inducer: Applied Workflows & Insigh

  2026-06-07

  Erastin is a gold-standard ferroptosis inducer, uniquely enabling researchers to dissect iron-dependent, non-apoptotic cell death in RAS/BRAF-mutant and aging models. This guide details advanced protocols, troubleshooting, and practical innovations, leveraging the latest findings to optimize ferroptosis research in cancer biology and redox vulnerability studies.

• nor-Binaltorphimine dihydrochloride in Opioid Receptor Antag

  2026-06-06

  nor-Binaltorphimine dihydrochloride stands at the forefront of opioid receptor signaling research, enabling precise interrogation of κ-opioid pathways in pain modulation and tolerance. This article provides actionable workflows, troubleshooting strategies, and expert guidance to maximize its impact in experimental neuropharmacology.

• Magneto-Piezoelectric Scaffolds Activate JAK2/STAT3 in Bone

  2026-06-05

  The referenced ACS Nano study introduces engineered magneto-piezoelectric nanoparticle-enhanced scaffolds that disrupt biofilms and activate oxidative phosphorylation via JAK2/STAT3 signaling in Icam1+ macrophages, promoting bone regeneration in infectious defects. This approach integrates biofilm management and immunomodulation, offering a promising direction for orthopedic tissue engineering.

• GSH and GSSG Assay Kit: Precision Redox Metrics for Tumor Me

  2026-06-05

  Explore how the GSH and GSSG Assay Kit empowers advanced reduced glutathione detection and oxidized glutathione measurement in the context of tumor metabolic reprogramming. This article uniquely connects practical assay workflows with the latest immunometabolic insights, offering actionable guidance for oxidative stress research.

• AI-10-49: Selective CBFβ-SMMHC Inhibitor for Leukemia Resear

  2026-06-04

  AI-10-49 is a potent small-molecule CBFβ-SMMHC inhibitor with nanomolar activity, enabling targeted disruption of oncogenic fusion proteins in acute myeloid leukemia. Its mechanism restores RUNX1 function and impairs leukemic cell survival, as validated in cell lines and animal models. This product dossier details benchmarks, mechanistic rationale, and real-world integration for acute myeloid leukemia research.

• Doxycycline Hyclate as a Matrix Metalloproteinases Inhibitor

  2026-06-04

  Doxycycline hyclate enables precise inhibition of MMP-2 and MMP-9, making it indispensable for dissecting blood-brain barrier (BBB) disruption and neuroprotection mechanisms. Its robust solubility and well-characterized dosage parameters streamline in vivo and in vitro neurovascular workflows for translational research.

408 records 12/28 page Previous Next First page 上5页 1112131415 下5页 Last page